Research peptides
CJC-1295 (senza dac)+ Ipamorelin
Available documentary data and items still to verify are detailed below.
Price incl. VAT€59.00
AvailabilityAvailable
SKUCJC1295+IPAMORELIN
Loading availability…
02 — Information to verify
Product details
Overview
This blend combines a GHRH analogue listed as CJC-1295 without DAC with ipamorelin, a pentapeptide studied as a growth-hormone secretagogue. The two components are associated with different receptor systems.
Structure and technical data
Technical data
Catalog amounts: 5 mg + 5 mg. A blend does not have a single sequence or molecular formula. Component sequences, salt forms, and analytical proportions require separate specifications.
Structure not available.
- Sequence
- Not documented
- Molecular formula
- Not documented
- Reported molecular mass
- Not documented
- CAS number
- Not documented
- PubChem CID
- Not documented
- Reported synonyms
- Not documented
Reference molecular data.
Single-molecule fields do not apply to this blend. Identification of its two components requires separate specifications; the name “without DAC” is not interchangeable with the version with DAC.
Research context
Research context includes the GHRH receptor and the GH-secretagogue receptor, GHS-R. Studies of CJC-1295 with DAC cannot be directly transferred to the version without DAC or to the combination.
CJC-1295 without DAC componentIpamorelin and the secretagogue receptorCombination and the meaning of synergyMuscle, lipids, and energy metabolismMotility, sleep, immunity, and attribution limits
CJC-1295 without DAC component
The name denotes a GHRH analogue without the DAC group associated with prolonged albumin-binding forms. GHRH-receptor stimulation is studied within the pituitary GH/IGF-1 axis. Pharmacokinetic properties of DAC-containing forms do not describe the version without DAC.
Ipamorelin and the secretagogue receptor
Ipamorelin is a pentapeptide investigated as a GH secretagogue. The original 1998 paper characterises its activity and selectivity in experimental systems. The secretagogue receptor, GHS-R, differs from the GHRH receptor; the blend components are not simply copies of the same molecule.
Combination and the meaning of synergy
Different mechanisms can be studied together, but synergy requires comparing separate components with their combination in the same model. The 5 mg + 5 mg amounts describe nominal composition, not effect size.
Muscle, lipids, and energy metabolism
GH and IGF-1 participate in protein synthesis, nutrient use, and lipid metabolism. Hormone increases, cellular-marker changes, and body-composition changes are different research endpoints. Axis physiology does not automatically demonstrate muscle growth or sports recovery from this combination.
Motility, sleep, immunity, and attribution limits
Secretagogue research also includes gastrointestinal motility and endocrine responses. Sleep, immune function, and ageing are broader physiological areas; attributing effects to the blend requires dedicated studies. Selectivity in one experiment does not mean absence of effects on other hormones in every context.
References
Catalog of products presented for research activities. Not for human or veterinary use. This notice does not replace verification of applicable rules.